Alatab, S. et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the...
Home > Press > HKUMed invents a novel two-dimensional (2D) ultrasound-responsive antibacterial nano-sheets to effectively address bone tissue infection
HKUMed invents a novel...
WAYNE, N.J.--(BUSINESS WIRE)-- Vision Research, a leading manufacturer of digital high-speed imaging systems, has for the first time supplied an embedded Phantom high-speed camera...
Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20, 533–534 (2020).Article CAS ...
StarFish Medical YouTube subscribers grew 50% in 2022. What medical device commercialization videos were they watching?Our 2022 top 10 medical device commercialization videos include...
Brooks S.M. Alper H.S. Applications, challenges, and needs for employing synthetic biology beyond the lab.Nat. Commun. 2021; 12: 1390View in Article Google ScholarLawson C.E....
CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Affinivax, Inc. (“Affinivax”) and Astellas Pharma Inc. (“Astellas”) today announced that they have entered into an agreement whereby Affinivax has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae. In conjunction with the rights reacquisition by Affinivax, ASP3772 will be renamed AFX3772. Closing of the transaction […]
